J&J leads a $25M A round for can­cer start­up; BMJ frets about Trump’s im­pact on the sci­en­tif­ic com­mu­ni­ty

• J&J In­no­va­tion has led a $25 mil­lion start­up round for Fu­sion Phar­ma­ceu­ti­cals. The Cana­di­an biotech is work­ing on tar­get­ed al­pha-par­ti­cle emit­ting ra­dio­ther­a­peu­tics which com­bine “the pre­ci­sion of mol­e­c­u­lar tar­get­ing agents, such as an­ti­bod­ies with the po­ten­cy of al­pha-par­ti­cle emit­ting ra­dioiso­topes to specif­i­cal­ly at­tack and erad­i­cate can­cer cells.” The com­pa­ny is a spin­out from Mc­Mas­ter Uni­ver­si­ty in On­tario. “Tar­get­ed de­liv­ery of med­ical iso­topes that emit al­pha par­ti­cles can be used to kill tu­mor cells with re­mark­able pre­ci­sion and un­prece­dent­ed po­ten­cy, and it has the added po­ten­tial of hav­ing com­ple­men­tary ef­fects with treat­ments which ac­ti­vate the im­mune sys­tem,” said Dr. John Val­liant, CEO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER